CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management
Panelists discuss the comparison between clinical trial results and real-world outcomes for chimeric antigen receptor T-cell (CAR T) therapies like liso-cel and axi-cel. Clinical trials have shown promising efficacy and manageable safety profiles for both therapies in treating certain blood cancers. However, real-world evidence continues to emerge through ongoing clinical use and registry data collection.
EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy
EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL
EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL
EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management
EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection
EP: 7.Personalizing CAR T: Making the Right Call for Each Patient
EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?
EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care
Video content above is prompted by the following:
- How do the efficacy and safety outcomes of liso-cel and axi-cel in clinical trials compare to what you have observed in real-world practice?
- Are there specific patient populations or clinical scenarios where you find the trial data align—or diverge—from real-world experiences with CAR T therapy?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
